FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1974941970> ?p ?o ?g. }

• W1974941970 endingPage "715" @default.
• W1974941970 startingPage "691" @default.
• W1974941970 abstract "Interferon injectables and glatiramer acetate have served as the primary disease-modifying treatments for multiple sclerosis (MS) since their introduction in the 1990s and are first-line treatments for relapsing-remitting forms of MS (RRMS). Many new drug therapies were launched since early 2010, expanding the drug treatment options considerably in a disease state that once had a limited treatment portfolio. The purpose of this review is to critically evaluate the safety profile and efficacy data of disease-modifying agents for MS approved by the US Food and Drug Administration (FDA) from 2010 to the present and provide cost and available pharmacoeconomic data about each new treatment.Peer-reviewed clinical trials, pharmacoeconomic studies, and relevant pharmacokinetic/pharmacologic studies were identified from MEDLINE (January 2000-December 2014) by using the search terms multiple sclerosis, fingolimod, teriflunomide, alemtuzumab, dimethyl fumarate, pegylated interferon, peginterferon beta-1a, glatiramer 3 times weekly, and pharmacoeconomics. Citations from available articles were also reviewed for additional references. The databases publically available at www.clinicaltrials.gov and www.fda.gov were searched for unpublished studies or studies currently in progress.A total of 5 new agents and 1 new dosage formulation were approved by the FDA for the treatment of RRMS since 2010. Peginterferon beta-1a and high-dose glatiramer acetate represent 2 new effective injectable options for MS that reduce burden of administration seen with traditional interferon and low-dose glatiramer acetate. Fingolimod, teriflunomide, and dimethyl fumarate represent new oral agents available for MS, and their efficacy in reducing annualized relapse rates is 48% to 55%, 22% to 36.3%, and 44% to 53%, respectively, compared with placebo. Alemtuzumab is a biologic given over a 2-year span that reduced annualized relapse rates by 55% in treatment-naive patients and by 49% in patients relapsing on prior disease-modifying agents. Treatment emergent adverse effects were common with all new drug treatments. The cost of treating MS remains high, because MS therapies accounted for the highest spending growth of any specialty drug class in 2013. Most therapies cost, on average, US $6000/mo based on wholesale acquisition cost, and few cost-benefit studies are available for new treatments.With expansion of new treatments, patients and providers now have multiple options and improved flexibility in managing MS. The relative place in therapy of new treatments is unknown, and treatment decisions are largely based on patient preference, efficacy, and risk potential. The cost of treating MS continues to be high, even with more treatment options available." @default.
• W1974941970 created "2016-06-24" @default.
• W1974941970 creator A5051451674 @default.
• W1974941970 creator A5052366712 @default.
• W1974941970 date "2015-04-01" @default.
• W1974941970 modified "2023-09-25" @default.
• W1974941970 title "New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis" @default.
• W1974941970 cites W1580917658 @default.
• W1974941970 cites W1666336517 @default.
• W1974941970 cites W1967838438 @default.
• W1974941970 cites W1968507597 @default.
• W1974941970 cites W1970693461 @default.
• W1974941970 cites W1972232744 @default.
• W1974941970 cites W1973751012 @default.
• W1974941970 cites W1982165854 @default.
• W1974941970 cites W1983382084 @default.
• W1974941970 cites W1983999022 @default.
• W1974941970 cites W1990785469 @default.
• W1974941970 cites W1992656196 @default.
• W1974941970 cites W1997880566 @default.
• W1974941970 cites W2005140078 @default.
• W1974941970 cites W2005611486 @default.
• W1974941970 cites W2007844082 @default.
• W1974941970 cites W2028474226 @default.
• W1974941970 cites W2041978490 @default.
• W1974941970 cites W2043591841 @default.
• W1974941970 cites W2047174864 @default.
• W1974941970 cites W2054574473 @default.
• W1974941970 cites W2056843315 @default.
• W1974941970 cites W2060125796 @default.
• W1974941970 cites W2061005334 @default.
• W1974941970 cites W2064775943 @default.
• W1974941970 cites W2070057263 @default.
• W1974941970 cites W2082461176 @default.
• W1974941970 cites W2089126944 @default.
• W1974941970 cites W2093009907 @default.
• W1974941970 cites W2096479500 @default.
• W1974941970 cites W2104948944 @default.
• W1974941970 cites W2107422246 @default.
• W1974941970 cites W2115933409 @default.
• W1974941970 cites W2117751925 @default.
• W1974941970 cites W2118735809 @default.
• W1974941970 cites W2119284493 @default.
• W1974941970 cites W2124417387 @default.
• W1974941970 cites W2129967156 @default.
• W1974941970 cites W2131078277 @default.
• W1974941970 cites W2131902490 @default.
• W1974941970 cites W2133329597 @default.
• W1974941970 cites W2135746117 @default.
• W1974941970 cites W2148766438 @default.
• W1974941970 cites W2151340435 @default.
• W1974941970 cites W2153518194 @default.
• W1974941970 cites W2155245449 @default.
• W1974941970 cites W2155409930 @default.
• W1974941970 cites W2156268561 @default.
• W1974941970 cites W2158202057 @default.
• W1974941970 cites W2161512169 @default.
• W1974941970 cites W2162412742 @default.
• W1974941970 cites W2332945656 @default.
• W1974941970 cites W2333473854 @default.
• W1974941970 cites W4211254511 @default.
• W1974941970 cites W4235426834 @default.
• W1974941970 doi "https://doi.org/10.1016/j.clinthera.2015.03.001" @default.
• W1974941970 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25846320" @default.
• W1974941970 hasPublicationYear "2015" @default.
• W1974941970 type Work @default.
• W1974941970 sameAs 1974941970 @default.
• W1974941970 citedByCount "109" @default.
• W1974941970 countsByYear W19749419702015 @default.
• W1974941970 countsByYear W19749419702016 @default.
• W1974941970 countsByYear W19749419702017 @default.
• W1974941970 countsByYear W19749419702018 @default.
• W1974941970 countsByYear W19749419702019 @default.
• W1974941970 countsByYear W19749419702020 @default.
• W1974941970 countsByYear W19749419702021 @default.
• W1974941970 countsByYear W19749419702022 @default.
• W1974941970 countsByYear W19749419702023 @default.
• W1974941970 crossrefType "journal-article" @default.
• W1974941970 hasAuthorship W1974941970A5051451674 @default.
• W1974941970 hasAuthorship W1974941970A5052366712 @default.
• W1974941970 hasConcept C126322002 @default.
• W1974941970 hasConcept C177713679 @default.
• W1974941970 hasConcept C203014093 @default.
• W1974941970 hasConcept C2776036978 @default.
• W1974941970 hasConcept C2776819417 @default.
• W1974941970 hasConcept C2777494893 @default.
• W1974941970 hasConcept C2777703276 @default.
• W1974941970 hasConcept C2778577042 @default.
• W1974941970 hasConcept C2779015954 @default.
• W1974941970 hasConcept C2780035454 @default.
• W1974941970 hasConcept C2780640218 @default.
• W1974941970 hasConcept C2911091166 @default.
• W1974941970 hasConcept C535046627 @default.
• W1974941970 hasConcept C71924100 @default.
• W1974941970 hasConcept C98274493 @default.
• W1974941970 hasConceptScore W1974941970C126322002 @default.
• W1974941970 hasConceptScore W1974941970C177713679 @default.
• W1974941970 hasConceptScore W1974941970C203014093 @default.

• next